Sandoz announced that the European Commission has granted marketing authorization for Afqlir® 2 mg vial kit and pre-filled syringe for intravitreal injection. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration.
[Sandoz]
